Scientists develop potent anthrax toxin inhibitor
Led by National Institute of Allergy and Infectious Diseases (NIAID) grantees from Rensselaer Polytechnic Institute and the University of Toronto, the investigators built a fatty bubble studded with
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).